TG Therapeutics.

TG Therapeutics secured a deal worth $645 million to license its multiple sclerosis treatment outside of North America. The pharmaceutical company disclosed a deal that grants Neuraxpharm Group an exclusive license to commercialize its treatment in Europe and other countries...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT